Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.

Shaimaa LasheenKyrillus S ShohdyLoay KassemOmar Abdel-Rahman

Published in: Expert review of anticancer therapy (2017)

CDK4/6 inhibitors were associated with an increased risk of fatigue, alopecia and stomatitis. Further studies with self-reported questionnaires may elucidate the impact of the increased risk of these selected adverse effects on the patients' quality of life.

Keyphrases

end stage renal disease
cell cycle
ejection fraction
newly diagnosed
chronic kidney disease
sleep quality
patient reported outcomes
protein kinase
cell cycle arrest
adverse drug